Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

NCT02942290 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02942290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02942290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
January 12, 2017
Completion date
April 15, 2026
Enrollment
134 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes (mds)